(Q36547786)

14 August 2017

1 reference

title

Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors (English)

1 reference

14 August 2017

L C Amler

1

1 reference

14 August 2017

A D Goddard

series ordinal

2

1 reference

14 August 2017

K J Hillan

series ordinal

3

1 reference

14 August 2017

publication date

1 January 2005

1 reference

Cold Spring Harbor Symposia on Quantitative Biology

14 August 2017

published in

1 reference

14 August 2017

volume

70

1 reference

14 August 2017

page(s)

483-488

1 reference

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Implications and prognostic value of K-ras mutation for early-stage lung cancer in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Gefitinib in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.048

21 January 2018

Identifiers

DOI

10.1101/SQB.2005.70.048

1 reference

14 August 2017

1 reference